Lefamulin or moxifloxacin for community-acquired pneumonia: balancing innovation, safety, and evidence
Abstract
The recent approval of lefamulin presents an alternative to fluoroquinolones for community-acquired pneumonia. In recent trials, lefamulin matched moxifloxacin in early clinical response and safety, with a favorable activity spectrum including atypical pathogens. However, fluoroquinolones remain entrenched due to cost, clinician familiarity, and broad guidelines. This letter examines current evidence comparing the two, highlights potential niches for lefamulin, and calls for more trials to guide adoption in diverse healthcare settings.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.